These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 21304398)

  • 21. The therapeutic efficacy of murine anti-tumor T cells: freshly isolated T cells are more therapeutic than T cells expanded in vitro.
    Evans R; Kamdar SJ; Duffy TM; Krupke DM; Fuller JA; Dudley ME
    Anticancer Res; 1995; 15(2):441-7. PubMed ID: 7763019
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selective expansion of a specific anti-tumor CD8+ cytotoxic T lymphocyte clone in the bulk culture of tumor-infiltrating lymphocytes from a melanoma patient: cytotoxic activity and T cell receptor gene rearrangements.
    Gervois N; Heuze F; Diez E; Jotereau F
    Eur J Immunol; 1990 Apr; 20(4):825-31. PubMed ID: 1971794
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Adoptive immunotherapy and metastasized cancer of the kidney. Regulator effects of interleukin-4 on tumor infiltrating lymphocytes (TIL)].
    Peyret C; Bochner B; Lee TY; Tso CL; Dekernion JB; Belldegrun A
    Chirurgie; 1991; 117(9):700-9. PubMed ID: 1843670
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Absence of amplification of CD4+CD25(high) regulatory T cells during in vitro expansion of tumor-infiltrating lymphocytes in melanoma patients.
    Knol AC; Lemaître F; Pandolfino MC; Volteau C; Quéreux G; Saiagh S; Khammari A; Viguier M; Dréno B
    Exp Dermatol; 2008 May; 17(5):436-45. PubMed ID: 18312383
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Study of tumor-infiltrating lymphocytes for adoptive therapy of renal cell carcinoma (RCC) and metastatic melanoma: sequential proliferation of cytotoxic natural killer and noncytotoxic T cells in RCC.
    Hayakawa K; Salmeron MA; Parkinson DR; Markowitz AB; von Eschenbach AC; Legha SS; Balch CM; Ross MI; Augustus LB; Itoh K
    J Immunother (1991); 1991 Oct; 10(5):313-25. PubMed ID: 1790139
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bimodal ex vivo expansion of T cells from patients with head and neck squamous cell carcinoma: a prerequisite for adoptive cell transfer.
    Junker N; Andersen MH; Wenandy L; Dombernowsky SL; Kiss K; Sørensen CH; Therkildsen MH; Von Buchwald C; Andersen E; Straten PT; Svane IM
    Cytotherapy; 2011 Aug; 13(7):822-34. PubMed ID: 21428850
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metastatic Lung Lesions as a Preferred Resection Site for Immunotherapy With Tumor Infiltrating Lymphocytes.
    Ben-Avi R; Itzhaki O; Simansky D; Zippel D; Markel G; Ben Nun A; Schachter J; Besser MJ
    J Immunother; 2016 Jun; 39(5):218-22. PubMed ID: 27163742
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of the CD4+ and CD8+ tumor infiltrating lymphocytes propagated with bispecific monoclonal antibodies.
    Wong JT; Pinto CE; Gifford JD; Kurnick JT; Kradin RL
    J Immunol; 1989 Nov; 143(10):3404-11. PubMed ID: 2509557
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enrichment of CD8+ cells from melanoma tumor-infiltrating lymphocyte cultures reveals tumor reactivity for use in adoptive cell therapy.
    Prieto PA; Durflinger KH; Wunderlich JR; Rosenberg SA; Dudley ME
    J Immunother; 2010 Jun; 33(5):547-56. PubMed ID: 20463593
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Simplified protocol for clinical-grade tumor-infiltrating lymphocyte manufacturing with use of the Wave bioreactor.
    Donia M; Larsen SM; Met O; Svane IM
    Cytotherapy; 2014 Aug; 16(8):1117-20. PubMed ID: 24831841
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intratumor gene expression after adoptive immunotherapy in a murine tumor model. Regulation of messenger RNA levels associated with the differential expansion of tumor-infiltrating lymphocytes.
    Evans R; Kamdar SJ; Duffy T; Edison L
    J Immunol; 1993 Jan; 150(1):177-84. PubMed ID: 8417123
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma.
    Dudley ME; Gross CA; Somerville RP; Hong Y; Schaub NP; Rosati SF; White DE; Nathan D; Restifo NP; Steinberg SM; Wunderlich JR; Kammula US; Sherry RM; Yang JC; Phan GQ; Hughes MS; Laurencot CM; Rosenberg SA
    J Clin Oncol; 2013 Jun; 31(17):2152-9. PubMed ID: 23650429
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proliferative, phenotypic and functional and molecular characteristics of tumour-infiltrating lymphocytes obtained from unselected patients with malignant melanomas and expanded in vitro in the presence of recombinant interleukin-2.
    Melioli G; Guastella M; Semino C; Meta M; Pietra G; Ponte M; Queirolo P; Sertoli MR; Martini L; Reali UM
    Melanoma Res; 1994 Apr; 4(2):127-33. PubMed ID: 8069098
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Large-scale expansion in interleukin-2 of tumor-infiltrating lymphocytes from patients with ovarian carcinoma for adoptive immunotherapy.
    Freedman RS; Tomasovic B; Templin S; Atkinson EN; Kudelka A; Edwards CL; Platsoucas CD
    J Immunol Methods; 1994 Jan; 167(1-2):145-60. PubMed ID: 8308273
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pulmonary macrophages suppress the proliferation and cytotoxicity of tumor-infiltrating lymphocytes.
    Swisher SG; Kiertscher SM; Golub SH; Holmes EC; Roth MD
    Am J Respir Cell Mol Biol; 1993 May; 8(5):486-92. PubMed ID: 8481233
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of tumor-infiltrating lymphocytes derived from human tumors for use as adoptive immunotherapy of cancer.
    Schiltz PM; Beutel LD; Nayak SK; Dillman RO
    J Immunother; 1997 Sep; 20(5):377-86. PubMed ID: 9336745
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen.
    Andersen R; Donia M; Ellebaek E; Borch TH; Kongsted P; Iversen TZ; Hölmich LR; Hendel HW; Met Ö; Andersen MH; Thor Straten P; Svane IM
    Clin Cancer Res; 2016 Aug; 22(15):3734-45. PubMed ID: 27006492
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Growth of tumor-infiltrating lymphocytes from human solid cancers: summary of a 5-year experience.
    Yannelli JR; Hyatt C; McConnell S; Hines K; Jacknin L; Parker L; Sanders M; Rosenberg SA
    Int J Cancer; 1996 Feb; 65(4):413-21. PubMed ID: 8621219
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2.
    Nguyen LT; Saibil SD; Sotov V; Le MX; Khoja L; Ghazarian D; Bonilla L; Majeed H; Hogg D; Joshua AM; Crump M; Franke N; Spreafico A; Hansen A; Al-Habeeb A; Leong W; Easson A; Reedijk M; Goldstein DP; McCready D; Yasufuku K; Waddell T; Cypel M; Pierre A; Zhang B; Boross-Harmer S; Cipollone J; Nelles M; Scheid E; Fyrsta M; Lo CS; Nie J; Yam JY; Yen PH; Gray D; Motta V; Elford AR; DeLuca S; Wang L; Effendi S; Ellenchery R; Hirano N; Ohashi PS; Butler MO
    Cancer Immunol Immunother; 2019 May; 68(5):773-785. PubMed ID: 30747243
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy.
    Tran KQ; Zhou J; Durflinger KH; Langhan MM; Shelton TE; Wunderlich JR; Robbins PF; Rosenberg SA; Dudley ME
    J Immunother; 2008 Oct; 31(8):742-51. PubMed ID: 18779745
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.